SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving NewLink Genetics Corporation and a Lead Plaintiff Deadline of July 11, 2016

NEW YORK, June 24, 2016

Click here to learn about the case: http://www.wongesq.com/pslra/newlink-genetics-corporation. There is no cost or obligation to you.

According to the complaint, NewLink continuously touted the effectiveness and favorable safety profile of the company's lead product candidate, algenpantucel-L, an immunotherapeutic pancreatic cancer treatment. As a result of such public statements, the stock price traded at artificially high levels throughout the class period.

On May 9, 2016, NewLink announced that algenpantucel-L did not achieve its primary endpoint. Patients treated with algenpantucel-L lived for a median of 27.3 months in NewLink's Phase 3 Clinical Trial, compared to median survival of 30.4 months for patients treated with standard therapy. Following this news, shares of NewLink were down more than 30% during intraday trading May 10, 2016.

If you suffered a loss in NewLink you have until July 11, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email vw@wongesq.com, by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/newlink-genetics-corporation.

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights.  Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:   
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com